Bio-Rad Laboratories, Inc. Class A Common Stock vs Occidental Petroleum Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.86 (market cap $8.04B), while Occidental Petroleum Corporation trades at $53.84 (market cap $54.28B). The key difference: Occidental Petroleum Corporation is far larger — about 6.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Occidental Petroleum Corporation pays a 1.91% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OXY | |
|---|---|---|
Market Cap | $8.04B | $54.28B |
Sector | Health | Energy |
52-Week High | $339.75 | $66.24 |
52-Week Low | $241.71 | $38.92 |
Enterprise Value | $7.85B | $75.36B |
Dividend Yield | — | 1.91% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Occidental Petroleum (OXY) trades at $54.81, up 3.63% with bullish technical signals and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is positive with 50% buy ratings and $66.14 price target, while recent news highlights operational improvements and geopolitical tailwinds from higher oil prices.
OXY presents a compelling investment case with earnings outperformance, debt reduction progress, and favorable oil price environment, but faces risks from commodity volatility and execution challenges in carbon capture initiatives. The stock's current valuation at 74x P/E requires sustained earnings growth to justify further upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →